<DOC>
	<DOC>NCT02597465</DOC>
	<brief_summary>An open label study to determine the efficacy and safety of SPARC1507</brief_summary>
	<brief_title>Study of SPARC1507</brief_title>
	<detailed_description>Subjects with advanced Biliary tract carcinoma meeting the eligibility criteria will be randomized in this study.</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<criteria>Evidence of advanced/metastatic biliary tract cancer Male or female ≥ 18 years old Participants must have measurable disease according to RECIST ECOG performance status ≤ 1 Known hypersensitivity to trial treatments, or their excipients Prior history of treatment with any taxane therapy Cardiovascular disorders as per Investigator's discretion The subject has received radiation therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>